Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Medications Don’t Slow T2D Progression in Youth

Diabetes Care; ePub 2018 Jun 25; RISE Consortium

In youth with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes (T2D), neither 3 months of glargine followed by 9 months of metformin nor 12 months of metformin alone slowed the progressive deterioration of β-cell function, a recent study found. 91 pubertal, overweight/obese youth aged 10-19 years with IGT (60%) or T2D of <6 months duration (40%) were randomized to either 3 months of insulin glargine with a target glucose of 4.4-5.0 mmol/L followed by 9 months of metformin or to 12 months of metformin alone. Researchers found:

  • No significant differences were found between treatment groups as baseline, 12 months, or 15 months in β-cell function, body mass index (BMI) percentile, HbA1c fasting glucose, or oral glucose tolerance test 2-h glucose results.
  • In both treatment groups, clamp-measured β-cell function was significantly lower at 12 and 15 months vs baseline.
  • HbA1c fell transiently at 6 months within both groups.
  • BMI was higher in the glargine followed by metformin vs metformin alone group between 3-9 months.

Citation:

The RISE Consortium. Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. [Published online ahead of print June 25, 2018]. Diabetes Care. doi:10.2337/dc18-0787.

This Week's Must Reads

Androgen Deprivation Therapy & Risk of Depression, Cancer; ePub 2019 Feb 12; Deka, Rose, et al

QOL in Patients with Low-Risk PC Treated with HRT, JAMA Oncol; ePub 2019 Feb 14; Bruner, et al

Hospital Competition & Prostate Cancer Outcomes, Cancer; ePub 2019 Feb 1; Aggarwal, et al

Insurance Status & Stage of Prostate Ca Diagnosis, Cancer Epidemiol; 2019 Apr; Ramirez, Morano, et al

Agent Orange Exposure & Prostate Ca Outcomes, J Urol; ePub 2019 Jan 8; Etheridge, et al

Must Reads in Diabetes

Insulin Management in Patients with T2D, Lancet; ePub 2019 Feb 22; Bergenstal, et al

Hospitalization Rates in Young-Onset Diabetes, Ann Intern Med; ePub 2019 Jan 15; Ke, Lau, et al

Long-Term Absolute Risk for CVD by FG Level, Diabetes Care; ePub 2019 Jan 7; Bancks, et al

Prediabetes Status & Lifestyle Modification , J Am Board Fam Med; 2019 Jan 4; Owei, et al

Second-Line ADMs & CV Events in T2D, JAMA Netw Open; ePub 2018 Dec 21; O’Brien, et al